ProShare Advisors LLC Has $2.03 Million Stock Holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH)

ProShare Advisors LLC lifted its holdings in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 41.2% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 22,646 shares of the medical equipment provider’s stock after purchasing an additional 6,606 shares during the quarter. ProShare Advisors LLC’s holdings in Lantheus were worth $2,026,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of LNTH. Janus Henderson Group PLC increased its stake in shares of Lantheus by 72.7% during the 4th quarter. Janus Henderson Group PLC now owns 6,198,689 shares of the medical equipment provider’s stock worth $554,583,000 after purchasing an additional 2,610,118 shares during the last quarter. Farallon Capital Management LLC increased its stake in shares of Lantheus by 79.9% during the 4th quarter. Farallon Capital Management LLC now owns 5,316,227 shares of the medical equipment provider’s stock worth $475,590,000 after purchasing an additional 2,361,000 shares during the last quarter. T. Rowe Price Investment Management Inc. increased its stake in shares of Lantheus by 40.5% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 1,509,332 shares of the medical equipment provider’s stock worth $135,025,000 after purchasing an additional 435,445 shares during the last quarter. Raymond James Financial Inc. acquired a new position in shares of Lantheus during the 4th quarter worth $36,183,000. Finally, Swedbank AB increased its stake in shares of Lantheus by 53.3% during the 4th quarter. Swedbank AB now owns 1,107,243 shares of the medical equipment provider’s stock worth $99,054,000 after purchasing an additional 385,000 shares during the last quarter. Institutional investors and hedge funds own 99.06% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the stock. StockNews.com upgraded shares of Lantheus from a “hold” rating to a “buy” rating in a research note on Thursday, May 8th. Truist Financial lowered their target price on shares of Lantheus from $127.00 to $117.00 and set a “buy” rating on the stock in a research note on Thursday, May 8th. Finally, B. Riley lowered their target price on shares of Lantheus from $127.00 to $122.00 and set a “buy” rating on the stock in a research note on Friday, March 21st. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Lantheus presently has a consensus rating of “Buy” and a consensus target price of $132.67.

Lantheus Price Performance

Shares of NASDAQ:LNTH opened at $76.83 on Wednesday. Lantheus Holdings, Inc. has a one year low of $75.00 and a one year high of $126.89. The company has a 50 day moving average of $96.20 and a 200-day moving average of $92.76. The stock has a market cap of $5.32 billion, a price-to-earnings ratio of 12.78 and a beta of 0.23.

Lantheus (NASDAQ:LNTH) last released its quarterly earnings data on Wednesday, May 7th. The medical equipment provider reported $1.53 earnings per share for the quarter, missing the consensus estimate of $1.64 by ($0.11). Lantheus had a return on equity of 44.29% and a net margin of 28.57%. The firm had revenue of $372.76 million for the quarter, compared to the consensus estimate of $377.37 million. During the same period in the previous year, the business earned $1.69 EPS. The firm’s revenue was up .8% compared to the same quarter last year. Equities research analysts anticipate that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current year.

Insider Transactions at Lantheus

In other Lantheus news, CFO Robert J. Jr. Marshall sold 10,000 shares of the company’s stock in a transaction on Monday, March 17th. The shares were sold at an average price of $100.52, for a total transaction of $1,005,200.00. Following the sale, the chief financial officer now directly owns 113,860 shares of the company’s stock, valued at approximately $11,445,207.20. This represents a 8.07% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Mary Anne Heino sold 53,107 shares of the company’s stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $94.35, for a total transaction of $5,010,645.45. Following the completion of the transaction, the director now owns 440,399 shares in the company, valued at approximately $41,551,645.65. This represents a 10.76% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 63,109 shares of company stock valued at $6,016,046 over the last 90 days. 1.50% of the stock is owned by corporate insiders.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.